AU2020398147A1 - Methods and compositions for the treatment and prevention of Type 1 diabetes - Google Patents

Methods and compositions for the treatment and prevention of Type 1 diabetes Download PDF

Info

Publication number
AU2020398147A1
AU2020398147A1 AU2020398147A AU2020398147A AU2020398147A1 AU 2020398147 A1 AU2020398147 A1 AU 2020398147A1 AU 2020398147 A AU2020398147 A AU 2020398147A AU 2020398147 A AU2020398147 A AU 2020398147A AU 2020398147 A1 AU2020398147 A1 AU 2020398147A1
Authority
AU
Australia
Prior art keywords
amino acid
insulin
acid sequence
alpha chain
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020398147A
Other languages
English (en)
Inventor
Mary S. MORRIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Mary Morris & Associates LLC
Original Assignee
Dr Mary Morris & Associates LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Mary Morris & Associates LLC filed Critical Dr Mary Morris & Associates LLC
Publication of AU2020398147A1 publication Critical patent/AU2020398147A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2020398147A 2019-12-06 2020-11-25 Methods and compositions for the treatment and prevention of Type 1 diabetes Pending AU2020398147A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962944503P 2019-12-06 2019-12-06
US62/944,503 2019-12-06
PCT/US2020/062159 WO2021113136A1 (en) 2019-12-06 2020-11-25 Methods and compositions for the treatment and prevention of type 1 diabetes

Publications (1)

Publication Number Publication Date
AU2020398147A1 true AU2020398147A1 (en) 2022-06-02

Family

ID=76222225

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020398147A Pending AU2020398147A1 (en) 2019-12-06 2020-11-25 Methods and compositions for the treatment and prevention of Type 1 diabetes

Country Status (12)

Country Link
US (1) US12551537B2 (https=)
EP (2) EP4623900A3 (https=)
JP (1) JP2023505190A (https=)
CN (1) CN115151273A (https=)
AR (1) AR122339A1 (https=)
AU (1) AU2020398147A1 (https=)
CA (1) CA3159054A1 (https=)
DK (1) DK4069278T3 (https=)
FI (1) FI4069278T3 (https=)
PL (1) PL4069278T3 (https=)
TW (1) TW202133876A (https=)
WO (1) WO2021113136A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3159054A1 (en) * 2019-12-06 2021-06-10 Mary S. MORRIS Methods and compositions for the treatment and prevention of type 1 diabetes
CN116847869A (zh) * 2020-10-08 2023-10-03 美商玛丽莫里斯博士联合有限责任公司 用于治疗和预防1型糖尿病的方法和组合物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5487898A (en) 1991-08-26 1996-01-30 Abbott Laboratories Compositions and method for the sublingual or buccal administration therapeutic agents
EP1523993A1 (en) * 1999-12-16 2005-04-20 Eli Lilly & Company Polypeptide compositions with improved stability
CN1409640A (zh) * 1999-12-16 2003-04-09 伊莱利利公司 稳定性改善的多肽组合物
CA2500715A1 (en) * 2002-10-03 2004-04-15 Epimmune Inc. Hla binding peptides and their uses
PL1633876T3 (pl) * 2003-06-17 2009-01-30 Sembiosys Genetics Inc Sposoby wytwarzania insuliny w roślinach
US20070027063A1 (en) 2004-01-12 2007-02-01 Mannkind Corporation Method of preserving the function of insulin-producing cells
EP1725254A4 (en) 2004-02-04 2008-02-13 Univ Columbia ANTI-CD3 IMMUNOTHERAPY AND SPECIFIC ANTIGENS FOR THE TREATMENT OF AUTOIMMUNITY
US7279457B2 (en) 2004-03-12 2007-10-09 Biodel, Inc. Rapid acting drug delivery compositions
US20090023630A1 (en) 2005-01-31 2009-01-22 Jan Wouter Drijfhout Methods and Means for Use in Diagnostics and Treatment of Diabetes
AU2011202239C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
WO2012104834A1 (en) * 2011-02-03 2012-08-09 Pharmedica Ltd. New oral dissolving films for insulin administration, for treating diabetes
JP2015514126A (ja) 2012-04-16 2015-05-18 アルク−アベッロ エイ／エスＡｌｋ−Ａｂｅｌｌｏ Ａ／Ｓ 非特異的アレルギー免疫療法において使用するための植物プロフィリンポリペプチド
TW201625668A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
EP3215128B1 (en) * 2014-11-04 2019-09-04 Innopharmax, Inc. Oral administration of unstable or poorly-absorbed drugs
US10905727B2 (en) 2016-01-14 2021-02-02 Intrexon Actobiotics N.V. Compositions and methods for the treatment of type 1 diabetes
WO2018144867A1 (en) * 2017-02-03 2018-08-09 Vanderbilt University Systems, compositions and methods for treating diabetes
EP3589271A4 (en) 2017-02-28 2021-01-06 Biolingus IP LLC OIL BASED FORMULATIONS FOR SUBLINGUAL AND BUCCAL ADMINISTRATION
EP3418738A1 (en) 2017-06-23 2018-12-26 Klinikum rechts der Isar der Technischen Universität München A ratio of immune cells as prognostic indicator of therapeutic success in allergen-specific immunotherapy
PL3954384T3 (pl) 2017-09-08 2025-10-27 Diamyd Medical Ab Stratyfikacja genotypów w leczeniu i profilaktyce cukrzycy
CA3159054A1 (en) * 2019-12-06 2021-06-10 Mary S. MORRIS Methods and compositions for the treatment and prevention of type 1 diabetes
CN116847869A (zh) 2020-10-08 2023-10-03 美商玛丽莫里斯博士联合有限责任公司 用于治疗和预防1型糖尿病的方法和组合物

Also Published As

Publication number Publication date
EP4623900A3 (en) 2025-12-10
US20230018324A1 (en) 2023-01-19
CN115151273A (zh) 2022-10-04
CA3159054A1 (en) 2021-06-10
EP4623900A2 (en) 2025-10-01
WO2021113136A1 (en) 2021-06-10
TW202133876A (zh) 2021-09-16
JP2023505190A (ja) 2023-02-08
DK4069278T3 (da) 2025-06-30
EP4069278A1 (en) 2022-10-12
AR122339A1 (es) 2022-09-07
US12551537B2 (en) 2026-02-17
PL4069278T3 (pl) 2025-10-06
EP4069278B1 (en) 2025-06-11
EP4069278A4 (en) 2024-01-10
FI4069278T3 (fi) 2025-07-16

Similar Documents

Publication Publication Date Title
EP1928499B1 (en) Use of a dpp-iv inhibitor to reduce hypoglycemic events
Bhavsar et al. Evolution of exenatide as a diabetes therapeutic
EP1988100B1 (en) Derivatives of glucagon-like peptide-2 and their therapeutic use
Thomas et al. Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial
US20060105954A1 (en) Glucagon-like peptide-2 and its therapeutic use
JP2017075196A (ja) 医薬組成物、治療方法及びその使用
ZA200109925B (en) GLP-1 as a diagnostic test to determine beta-cell function and the presence of the condition of IGT and type-II diabetes.
AU2005271526B2 (en) Antidiabetic oral insulin-biguanide combination
US20160136246A1 (en) Novel Uses of GLP-1 Receptor Agonists in Patients Treated with Insulin and/or Suffering from Type 1 Diabetes
US12551537B2 (en) Methods and compositions for the treatment and prevention of type 1 diabetes
EP0835129B1 (en) Prevention of a disease having the characteristics of diabetes
EP4225352A1 (en) Methods and compositions for the treatment and prevention of type 1 diabetes
HK40078570B (en) Methods and compositions for the prevention of type 1 diabetes
HK40078570A (en) Methods and compositions for the prevention of type 1 diabetes
US20230012936A1 (en) Combination therapy using glucagon and glp-1 co-agonists for the treatment of obesity
Ohneda Effect of Glicentin-Related Peptides on Endocrine Function of Pancreas in Dogs¹
JP2022522461A (ja) 代謝性障害の処置のための組換えタンパク質の使用
Schopman et al. EFFECTS OF 6 WEEKS TREATMENT WITH A DIPEPTIDYLPEPTIDASE 4 INHIBITOR ON COUNTERREGULATORY AND INCRETIN HORMONES DURING ACUTE HYPOGLYCAEMIA IN PATIENTS WITH TYPE 1 DIABETES: A RANDOMIzED DOUBLE BLIND PLACEBO-CONTROLLED CROSS-OVER STUDy
HK1125653A (en) Derivatives of glucagon-like peptide-2 and their therapeutic use
HK1153482A (en) Glucagon-like peptide-2 derivatives and their therapeutic use
HK1149720A (en) Glucagon-like peptide-2 and its therapeutic use